EU approves Otsuka's long-acting HAE drug Dawnzera An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.

#hereditaryangioedema #Otsuka #Ionis #Dawnzera #regulatoryapproval #Rarediseases #pharmanews #HAEdrug #Dawnzera #antisenseoligonucleotidebasedplasmaprekallikreininhibitor #PKKinhibitor #plasmaprekallikreininhibitor #PKK #EMA #HAEpatients #clinicaltrials #RNAtargetedtherapy
zurl.co/Zw7sM

Biotech Ionis Pharmaceuticals surges 35% after upbeat trial of triglyceride drug – Oninvest Quotes of biotech Ionis Pharmaceuticals jumped 35% in a single day after it announced a successful trial of a drug that reduces triglyceride levels in the blood and prevents cases of acute pancreatiti...

2/ Already FDA-approved for a rare disorder (FCS), #Ionis now plans to seek wider approval — potentially unlocking a $1.7B market and access for 1M+ high-risk patients by 2026: en.oninvest.com/article/biot...

Two pharma companies developing #lipidlowering drugs, #MSD and #Ionis, have reported positive phase 3 data that open the way for #regulatory filings in the coming months.

pharmaphorum.com/news/msd-ion...

Mark this post: #Alnylam will regret not having done #CRISPR deals during this downturn. Ideal life-cycle, market segmentation complement. #Ionis has done it before with #Metagenomi. Metagenomi trades 70% below cash.

collaborer avec la future génération d’ingénieurs passionnés par l'aviation et l'espace !

📸 Photo : Photosphere IPSA TLS

#AATLSE #AilesAnciennesToulouse #IPSA #IPSAretro #Partnership #Engineering #Innovation #Aviation #Space #Aerospace #Toulouse #IONIS
3/3